English Overview
We are pleased to invite you to the webinar titled ‘Uncover New Possibilities in the Treatment of Moderate to Severe Atopic Dermatitis' This interactive webinar aims to share with the dermatology community the unmet needs of Atopic Dermatitis patients as well as the safety and efficacy of JAK selectivity in clinical trials.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
- An overview of Atopic Dermatitis disease and its importance in KSA.
- Addressing the unmet needs of Atopic Dermatitis patients.
- Improving Atopic Dermatitis skin signs and symptoms by targeting JAK1/2.
- Implications of targeting JAK1/2 might have on safety signals.
- The importance of interpreting safety concerns as well as JAK selectivity in the context of the safety profile in clinical trials.
- Clinical practice data that shows the characteristics of Baricitinib molecule beyond JAK inhibition.
- Addressing the unmet needs of Atopic Dermatitis patients.
- Improving Atopic Dermatitis skin signs and symptoms by targeting JAK1/2.
- Implications of targeting JAK1/2 might have on safety signals.
- The importance of interpreting safety concerns as well as JAK selectivity in the context of the safety profile in clinical trials.
- Clinical practice data that shows the characteristics of Baricitinib molecule beyond JAK inhibition.
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Uncover New Possibilities in the Treatment of Moderate to Severe Atopic Dermatitis Certificate
Certificate |
Certificate | Free |
VAT 15% Included
